Roivant Sciences

An investment of $10,000 in Roivant Sciences three years ago would, according to calculations, have grown to $43,183.43, based on a current price of $36.49 per share and roughly 1,183.43 shares held. That corresponds to an increase of 331.83 percent. Market capitalization was most recently $26.36 billion; stock splits and dividends were not taken into account in the calculation. » More on finanzen.net

At the Citi “Biopharma Back to School Summit,” Roivant outlined its three strategic pillars: brepocitinib (LISRAYA) with FDA approval for dermatomyositis, the promising inhaled mosliciguat for PH‑ILD, and the FcRn antagonist IMVT‑1402 with strong early RA data. The company highlighted a robust liquidity position of $3.9 billion (plus an expected Moderna contingent payment of >$700 million) and a market capitalization near $30 billion, which it says provides room for development and business activities. Roivant announced several near‑term catalysts (Phase III/II data in 2026–2027), but is pursuing a moderate launch and pricing strategy and noted an ongoing legal dispute related to an LNP study. » More on de.investing.com

Roivant presented convincing phase II data on mosliciguat at a conference, showing the strongest ever measured reduction in pulmonary vascular resistance and expanding indication planning beyond PH‑ILD. Brepocitinib was introduced early for dermatomyositis and received positive initial feedback, while IMVT‑1402 (FcRn program) is considered the third major long‑term project, with an important Graves' disease phase III program planned for 2027. Management emphasizes that operational capacity (simultaneous phase III studies) is the main constraint on growth, not capital; patent protection for mosliciguat extends into the mid‑2040s. » More on de.investing.com